This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neuropathic heredofamilial amyloidosis (transthyretin amyloidosis, Portuguese type)Neuropathic Heredofamilial Amyloidosis (TTR Amyloidosis / Portuguese Type)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E85.1 | Special Copayment Reduction: V121
B. SynonymsAmyloid polyneuropathy (Portuguese), neuropathic heredofamilial amyloidosis, familial amyloid polyneuropathy (FAP), ATTRv amyloidosis, TTR Val30Met amyloidosis
C. Adult onsetHigh likelihood of first onset in adulthood — the Portuguese type usually appears in the 30s–40s, with adult onset typical; the late-onset form can also begin in the 50s–60s
1. HistoryFirst described by Andrade in Portugal in 1952; Val30Met mutation identified by Costa et al. in 1984
2. CausesAmyloid fibril formation and tissue deposition of variant transthyretin protein due to TTR gene mutations
3. GeneticsAutosomal dominant, TTR gene 18q12.1, Val30Met (p.Val50Met) mutation most common
4. EpidemiologyEndemic distribution in Portugal (high frequency in the Póvoa de Varzim region), Sweden, and Japan; worldwide prevalence about 50,000 or more
5. PathophysiologyInstability of the variant TTR tetramer → monomer dissociation → amyloid fibril formation → deposition in peripheral nerves, heart, and autonomic nerves
6. SymptomsProgressive sensorimotor polyneuropathy (beginning in the lower limbs), autonomic dysfunction (orthostatic hypotension, gastroparesis, voiding dysfunction), cardiac abnormalities
7. SignsDistal lower limb sensory loss, muscle weakness, decreased tendon reflexes, orthostatic drop in blood pressure, arrhythmia, cardiomegaly
8. ScreeningConfirmation of family history, nerve conduction studies, echocardiography, serum TTR protein electrophoresis, genetic testing recommended
9. DiagnosisTissue biopsy (abdominal wall fat, rectum, nerve) with Congo red staining + TTR immunohistochemistry, TTR gene sequencing
10. TreatmentTTR stabilizers (tafamidis, diflunisal), RNA silencing therapies (patisiran, inotersen, vutrisiran), liver transplantation
11. PrognosisWithout treatment, death within 10–15 years after onset; progression can be suppressed with early treatment; survival improves after liver transplantation
12. PreventionFamily screening through genetic testing, presymptomatic monitoring, genetic counseling, preimplantation genetic diagnosis
13. ReferencesAdams et al. N Engl J Med 2018 and 9 other papers

1. History

Neuropathic heredofamilial amyloidosis (Portuguese type) became known academically in 1952, when the Portuguese neurologist Mário Corino de Andrade first systematically described a progressive polyneuropathy occurring in clusters in the fishing villages of Póvoa de Varzim and Vila do Conde in the coastal region north of Porto. Andrade reported that this disease was a fatal hereditary neurological disease characterized mainly by pain and sensory abnormalities in the distal lower limbs, autonomic dysfunction, and cachexia, and the name Portuguese-type familial amyloid polyneuropathy (FAP) subsequently came into common use in the literature.

In the 1960s, similar clinical features were also reported in the Kyushu region of Japan and the Skellefteå region of northern Sweden, identifying independent endemic areas sharing the same pathological mechanism. In 1978 Costa et al. discovered that the disease was associated with an abnormal serum prealbumin, that is, a variant of the transthyretin protein. Finally, in 1984, molecular genetic studies revealed that the Val30Met mutation, in which valine (Val) at codon 30 of the TTR gene is replaced by methionine (Met), is the main cause of the disease.

In the 1990s, the concept that liver transplantation could suppress disease progression by replacing the liver, the main organ producing variant TTR, was introduced and applied clinically. Then, from the 2010s, TTR stabilizers and RNA-based therapeutics were developed, rapidly changing the treatment paradigm. The disease is now commonly regarded as the representative subtype of hereditary transthyretin amyloidosis (ATTRv amyloidosis) caused by TTR gene variants, and more than 120 TTR mutations have been reported worldwide.

2. Causes

The direct cause of Portuguese-type neuropathic heredofamilial amyloidosis is abnormal amyloid fibril formation by variant transthyretin (variant TTR, ATTRv) protein due to pathogenic mutations of the TTR gene, and its deposition in various tissues such as the peripheral nervous system, autonomic nervous system, and heart.

Transthyretin is a serum protein normally synthesized mostly (about 95%) in the liver, and it transports thyroid hormone (thyroxine, T4) and, through a complex with retinol-binding protein, vitamin A in the blood. Normal TTR stably maintains a homotetramer structure composed of 4 identical monomers, but when mutations such as Val30Met occur, the thermodynamic stability of the tetramer decreases markedly.

Destabilized tetramers have an increased tendency to dissociate into monomers, and in this process abnormal protein folding (misfolding) occurs, forming amyloid fibrils rich in beta-sheet structure. The amyloid fibrils formed accumulate progressively, particularly in the endoneurial connective tissue of peripheral nerves, the cardiac interstitium, kidneys, eyes, and leptomeningeal vessels of the central nervous system, causing structural and functional damage to the affected organs. Amyloid deposition is known to cause nerve damage not only through direct mechanical compression but also through the cytotoxicity of oligomeric intermediates generated during fibril formation.

3. Genetics

The TTR gene is located on chromosome 18q12.1 and consists of 7 exons. This gene encodes the transthyretin protein consisting of 127 amino acids. The prototypical mutation of the Portuguese type is the c.148G>A variant in exon 2 of the TTR gene, the Val30Met (p.Val50Met) mutation in which valine (Val) at codon 30 (codon 50 in mature protein numbering) is replaced by methionine (Met).

The mode of inheritance is autosomal dominant, and theoretically heterozygous carriers transmit the mutation to 50% of their children. However, this disease is well known to show incomplete penetrance, and especially in the Swedish-type patient group there are many gene carriers who do not develop the disease even by age 80. In the endemic areas of Portugal and Japan, penetrance is relatively high, and more than 80% of carriers are reported to eventually develop the disease.

In addition to Val30Met, more than 120 pathogenic TTR mutations have been reported, including Val122Ile (mainly cardiac type, common in African Americans), Thr60Ala (Ireland, northwestern United States), Glu89Gln, and Ser77Tyr, and each mutation differs in clinical phenotype (neuropathic, cardiac, mixed), age of onset, and rate of progression. In Val30Met, two subtypes are distinguished, an early-onset form (30s–40s) and a late-onset form (50s–70s); the early-onset form is relatively more common in Portugal and Japan, and the late-onset form in Sweden and North America.

Modifier genes affecting gene penetrance, such as RBP4 and APOE polymorphisms, are being studied but have not yet been clearly established. Anticipation of the age of onset across generations within families is also observed in some, and there are reports that the age of onset may be earlier with maternal inheritance than with paternal inheritance.

4. General epidemiology

Neuropathic heredofamilial amyloidosis (Portuguese type, Val30Met) traditionally shows an endemic distribution in three regions: Portugal, Sweden, and Japan. In Portugal, centered on the Póvoa de Varzim and Vila do Conde areas, prevalence is estimated to reach about 1,000 per 100,000 population, the highest in the world. In Sweden, about 1,000 patients are estimated, centered on Västerbotten County in the north, and in Japan it occurs in clusters centered on the Kyushu region (Kumamoto, Nagasaki).

Worldwide, the number of patients with all ATTRv amyloidosis including Val30Met is estimated at about 50,000 or more, and the actual number is thought to be higher because of lack of awareness and diagnostic delay. Sporadic cases are also reported in nonendemic areas through immigrant populations or new mutations. The sex ratio is generally equal or tends to be slightly higher in males. In Korea it is very rare, but several cases have been reported in the literature, and accurate domestic prevalence data are limited.

The mean age of onset in early-onset (Portuguese-type) patients is the 30s–40s, and in the late-onset (Swedish-type) form it is the 50s–70s. There is an asymptomatic latent period of decades before onset, and early detection of asymptomatic carriers through genetic testing is important.

5. Pathophysiology

Under normal conditions, the TTR protein forms a stable homotetramer of 4 bound monomers and transports thyroid hormone and vitamin A via the T4 binding site. Pathogenic TTR variants, including the Val30Met mutation, lower the thermodynamic stability of the tetramer, promoting dissociation into monomers even under physiological conditions.

The dissociated monomers pass through a partially unfolded state to form pre-amyloid oligomers, which grow through nucleation into insoluble amyloid fibrils with repeated beta-sheet structure. These fibrils show the characteristic histologic finding of apple-green birefringence on Congo red staining. Amyloid deposition occurs mainly in the endoneurial and epineurial connective tissue of peripheral nerves and around endoneurial vessels, damaging both large- and small-diameter nerve fibers through increased endoneurial pressure, ischemia, and direct cytotoxicity.

In particular, unmyelinated nerve fibers (C fibers) and thinly myelinated fibers (Aδ fibers) are involved early, so pain, loss of temperature sensation, and autonomic dysfunction appear first; later, as large myelinated fibers become involved, loss of vibration sensation and motor weakness are added. Deposition in autonomic ganglia and the cardiac conduction system is also common, causing orthostatic hypotension, arrhythmia, and cardiac conduction block. Amyloid deposition in the vitreous body can cause decreased vision, and perivascular deposition in the leptomeninges rarely causes central nervous system symptoms.

6. Symptoms

The initial symptoms of Portuguese-type ATTRv amyloidosis are mostly sensory abnormalities beginning in the distal lower limbs. Patients first experience small fiber neuropathy symptoms such as stabbing pain, burning, and paresthesia (dysesthesia) in the feet and ankles. Characteristic early features include an odd sensation as if stepping on thick cotton under the feet, and reversal of temperature sensation, feeling cold as warm or vice versa.

Autonomic dysfunction appears early and prominently and greatly reduces patients' quality of life. Orthostatic hypotension (dizziness or syncope on standing from lying down), decreased gastric motility (early satiety, nausea, vomiting), alternating bowel disturbance with recurrent constipation and diarrhea, erectile dysfunction (men), and bladder dysfunction (difficulty voiding, residual urine, incontinence) are common. These autonomic symptoms are also a major cause of diagnostic delay.

As the disease progresses, motor nerves are also involved, and distal muscle weakness and gait disturbance appear. Cardiac symptoms may include palpitations, exertional dyspnea, edema, and syncope, and in some patients carpal tunnel syndrome appears first as a preceding symptom. Ophthalmologically, blurred vision due to vitreous amyloid deposition can occur, and glaucoma may be a complication. Decreased renal function and proteinuria are also observed in some patients.

7. Signs

On physical examination, the earliest neurological sign is loss of pain and temperature sensation in the distal lower limbs, reflecting small fiber involvement. Subsequently, loss of vibration and joint position sense is added, and decreased or absent tendon reflexes below the knee (Achilles reflex) are observed. Muscle atrophy becomes marked in the ankles and intrinsic foot muscles in advanced cases and can cause foot drop.

Autonomic signs include a drop in systolic blood pressure of 20 mmHg or more or diastolic blood pressure of 10 mmHg or more (orthostatic hypotension) on blood pressure measurement in the supine and standing positions. On abdominal examination, abdominal distension or decreased bowel sounds suggesting reduced gastrointestinal motility may be observed.

On cardiac examination, signs of heart failure such as cardiomegaly, a third heart sound, jugular venous distension, and lower limb edema may appear, and the ECG may show low voltage, AV block, bundle branch block, and various arrhythmias. On ophthalmologic examination, smoke-like amyloid deposits in the vitreous may be found on slit-lamp examination. Rarely, headache, visual disturbance, and cranial nerve palsies due to leptomeningeal deposition can occur.

8. Screening

Investigation of family history is the most basic screening tool. When a parent or sibling has a history of unexplained polyneuropathy, cardiomyopathy, autonomic dysfunction, or early death, TTR genetic testing should be performed. For first-degree relatives of patients with confirmed ATTRv, genetic testing after genetic counseling is recommended regardless of symptoms.

Nerve conduction studies (NCS) and electromyography (EMG) are useful for confirming the presence and characteristics of polyneuropathy. Because NCS may be near normal early on due to small fiber involvement, quantitative sensory testing (QST) and measurement of intraepidermal nerve fiber density by punch skin biopsy are more sensitive for evaluating small fiber neuropathy.

Echocardiography is essential for evaluating left ventricular hypertrophy, granular sparkling, diastolic dysfunction, and other findings suggestive of cardiac amyloid deposition. Serum and urine protein electrophoresis and serum free light chain testing are performed to differentiate from AL amyloidosis. 99mTc-DPD or 99mTc-PYP myocardial scintigraphy shows high specificity for noninvasive diagnosis of ATTR cardiac amyloidosis. Cardiac biomarkers such as BNP/NT-proBNP and troponin are also used to assess the extent of cardiac involvement.

9. Diagnosis

Confirmation of ATTRv amyloidosis is achieved by demonstrating amyloid deposition on tissue biopsy and identifying a pathogenic mutation on TTR genetic testing. Among tissue biopsy sites, abdominal fat pad aspiration is the least invasive, with a sensitivity of 60–80%. Rectal biopsy, salivary gland biopsy, nerve biopsy (sural nerve), and endomyocardial biopsy may also be performed; because sensitivity differs by site, biopsy of multiple sites increases the diagnostic yield.

Amyloid deposition is confirmed by apple-green birefringence under polarized light microscopy on Congo red staining. Then, to identify the type of amyloid precursor protein, immunohistochemical staining with TTR antibodies or laser microdissection mass spectrometry (LMD-MS) is performed. LMD-MS is recognized as the standard method for most accurately identifying the type of amyloid precursor protein.

Confirmation is completed when a pathogenic mutation such as Val30Met is identified by TTR gene sequencing (Sanger or NGS). On cardiac magnetic resonance imaging (cardiac MRI), an extensive subendocardial and intramyocardial distribution pattern of late gadolinium enhancement (LGE) is highly specific for cardiac amyloidosis. For noninvasive confirmation, an algorithm combining positive 99mTc-DPD scintigraphy with negative serum/urine monoclonal protein findings without tissue biopsy has been validated in ATTR cardiomyopathy (however, biopsy is needed in the neuropathic form).

10. Treatment

Treatment of ATTRv amyloidosis is broadly divided into three strategies: suppression of TTR production, stabilization of the TTR tetramer, and promotion of amyloid fibril degradation. The goals of treatment are suppression of progression of neuropathy and cardiac involvement, maintenance of function, and improvement of quality of life.

TTR RNA silencing therapies

Patisiran (Onpattro) is a small interfering RNA (siRNA) agent targeting TTR mRNA that received US FDA approval in 2018. It is given by intravenous infusion every 3 weeks, and the phase 3 APOLLO clinical trial demonstrated that it significantly suppressed neuropathy progression and improved neuropathy scores (mNIS+7) (Adams et al., NEJM 2018). Inotersen (Tegsedi) is an antisense oligonucleotide (ASO) agent given by subcutaneous injection once weekly, and blood count and renal function monitoring are mandatory because of the risk of thrombocytopenia and glomerulonephritis. Vutrisiran (Amvuttra) is a GalNAc-conjugated siRNA with the advantage of subcutaneous injection once every 3 months and recently received clinical approval.

TTR tetramer stabilizers

Tafamidis (Vyndamax/Vyndaqel) is a drug that binds to the T4 binding site of the TTR tetramer and inhibits tetramer dissociation; in the neuropathic form, efficacy has been demonstrated in early-onset Portuguese and Swedish patients, and its indication has been extended to the cardiac form. Diflunisal is a nonsteroidal anti-inflammatory drug with an additional action of stabilizing the TTR tetramer, and because it is readily accessible, it can be used as an alternative in settings where tafamidis is unavailable.

Liver transplantation

Liver transplantation replaces the liver, the main TTR-producing organ, with a donor liver that produces normal TTR, and more than about 1,400 have been performed since the 1990s. It is most effective in suppressing neuropathy progression in early-onset (Portuguese-type, Val30Met) patients, but cardiac amyloidosis may continue to progress after liver transplantation due to wild-type TTR. Combined liver–heart transplantation is performed in some patients with cardiac involvement.

Symptomatic treatment

For orthostatic hypotension, sufficient fluid and sodium intake, compression stockings, midodrine, fludrocortisone, and others are used. Gabapentin, pregabalin, and amitriptyline are effective for neuropathic pain. Cardiac conduction disorders may require a permanent pacemaker and, depending on the indication, an implantable cardioverter-defibrillator (ICD). Nutritional support, physical therapy, occupational therapy, and a multidisciplinary team approach are recommended.

11. Prognosis

The prognosis of untreated ATTRv amyloidosis (Portuguese type) is poor, with mean survival of around 10–15 years after onset. Neuropathy progresses in stages, and many patients become unable to walk within 10 years after onset. The main causes of death are heart failure, sudden death from arrhythmia, and infectious complications associated with cachexia (pneumonia, sepsis).

The extent of cardiac involvement, age of onset, mutation type, and timing of treatment initiation have a decisive effect on prognosis. The early-onset form (Portuguese type, onset in the 30s–40s) tends to have relatively less cardiac involvement, so long-term survival may be better than in the late-onset form. In clinical trials, patients treated with patisiran or inotersen had meaningfully suppressed neuropathy progression compared with the placebo group, and partial recovery of nerve function was also reported in some. The 20-year survival rate of Val30Met patients who received early liver transplantation is reported to be about 55–60%.

Prognostic indicators include the NIS (Neuropathy Impairment Score), PND (polyneuropathy disability score), NT-proBNP, troponin, and echocardiographic left ventricular wall thickness. Low BMI, cardiac conduction abnormalities, and malnutrition are poor prognostic factors.

12. Prevention

Complete prevention of this disease (stopping its onset) is currently impossible, but it is possible to delay onset or suppress progression through identification of carriers by genetic testing and early intervention. Family screening (cascade genetic testing) is recommended for first-degree relatives of confirmed patients, and a genetic counseling professional should fully explain the implications of testing and the interpretation of results.

Regular neurological, cardiological, and ophthalmologic follow-up is recommended for asymptomatic TTR variant carriers. The follow-up interval varies with risk of onset and age, but generally nerve conduction studies, echocardiography, and autonomic function tests are performed annually. Some guidelines suggest that administration of preventive TTR stabilizers or RNA therapeutics may be considered in high-risk asymptomatic carriers (e.g., Portuguese type aged 40 or older), but this has not been established as standard treatment.

Preimplantation genetic testing (PGT) and prenatal genetic diagnosis can be offered to families wishing to prevent transmission of the disease. Psychological support within the family and links with patient organizations (rare disease support) are also important from a preventive standpoint. Management of cardiovascular risk factors (hypertension, diabetes, smoking) is recommended as an adjunctive measure to prevent aggravation of cardiac involvement.

13. References

  1. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. doi:10.1056/NEJMoa1716153. PMID: 29972753.
  2. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217-222. PMID: 33100054.
  3. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785-792. PMID: 22843282.
  4. Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625-638. PMID: 26560523.
  5. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. PMID: 30145929.
  6. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-1097. PMID: 22094129.
  7. Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. PMID: 23425518.
  8. Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733-742. PMID: 27929525.
  9. Conceição I, González-Duarte A, Obici L, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5-9. PMID: 26663401.
  10. Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve. 2018;57(5):829-837. PMID: 29044605.